Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers

Thu H. Truong, Carol A. Lange

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Steroid hormone receptors (SRs) have a multitude of functions in human biology and disease progression. The SR family of related ligand-activated transcription factors includes androgen, estrogen, glucocorticoid, mineralocorticoid, and progesterone receptors. Antiestrogen or estrogen receptor (ER)targeted therapies to block ER action remain the primary treatment of luminal breast cancers. Although this strategy is successful, ;40% of patients eventually relapse due to endocrine resistance. The majority of hormone-independent tumors retain some level of SR expression, but sidestep hormone ablation treatments. SRs are known to crosstalk extensively with kinase signaling pathways, and this interplay has been shown to bypass ER-targeted therapies in part by providing alternative proliferation and survival signals that enable hormone independence. Modified receptors adopt alternate conformations that resist antagonism or promote agonism. SR-regulated transcription and SR-binding events have been classically studied as single receptor events using single hormones. However, it is becoming increasingly evident that individual steroids and SRs rarely act alone. Emerging evidence shows that coexpressed SRs crosstalk with each other in hormone-driven cancers, such as breast and prostate. Crosstalk between related SRs allows them to modulate signaling and transcriptional responses to noncognate ligands. This flexibility can lead to altered genomic binding and subsequent changes in SR target gene expression. This review will discuss recent mechanistic advances in elucidating SR crosstalk and the implications for treating hormone-driven cancers. Understanding this crosstalk (i.e., both opposing and collaborative) is a critical step toward expanding and modernizing endocrine therapies and will ultimately improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)3897-3907
Number of pages11
JournalEndocrinology
Volume159
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Steroid Receptors
Hormones
Neoplasms
Estrogen Receptors
Ligands
Therapeutics
Mineralocorticoid Receptors
Estrogen Receptor Modulators
Glucocorticoid Receptors
Androgen Receptors
Progesterone Receptors

Cite this

Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers. / Truong, Thu H.; Lange, Carol A.

In: Endocrinology, Vol. 159, No. 12, 01.12.2018, p. 3897-3907.

Research output: Contribution to journalArticle

Truong, Thu H. ; Lange, Carol A. / Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers. In: Endocrinology. 2018 ; Vol. 159, No. 12. pp. 3897-3907.
@article{79ce25c16c6e40f8b76c6d0297a6d1c3,
title = "Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers",
abstract = "Steroid hormone receptors (SRs) have a multitude of functions in human biology and disease progression. The SR family of related ligand-activated transcription factors includes androgen, estrogen, glucocorticoid, mineralocorticoid, and progesterone receptors. Antiestrogen or estrogen receptor (ER)targeted therapies to block ER action remain the primary treatment of luminal breast cancers. Although this strategy is successful, ;40{\%} of patients eventually relapse due to endocrine resistance. The majority of hormone-independent tumors retain some level of SR expression, but sidestep hormone ablation treatments. SRs are known to crosstalk extensively with kinase signaling pathways, and this interplay has been shown to bypass ER-targeted therapies in part by providing alternative proliferation and survival signals that enable hormone independence. Modified receptors adopt alternate conformations that resist antagonism or promote agonism. SR-regulated transcription and SR-binding events have been classically studied as single receptor events using single hormones. However, it is becoming increasingly evident that individual steroids and SRs rarely act alone. Emerging evidence shows that coexpressed SRs crosstalk with each other in hormone-driven cancers, such as breast and prostate. Crosstalk between related SRs allows them to modulate signaling and transcriptional responses to noncognate ligands. This flexibility can lead to altered genomic binding and subsequent changes in SR target gene expression. This review will discuss recent mechanistic advances in elucidating SR crosstalk and the implications for treating hormone-driven cancers. Understanding this crosstalk (i.e., both opposing and collaborative) is a critical step toward expanding and modernizing endocrine therapies and will ultimately improve patient outcomes.",
author = "Truong, {Thu H.} and Lange, {Carol A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1210/en.2018-00831",
language = "English (US)",
volume = "159",
pages = "3897--3907",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers

AU - Truong, Thu H.

AU - Lange, Carol A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Steroid hormone receptors (SRs) have a multitude of functions in human biology and disease progression. The SR family of related ligand-activated transcription factors includes androgen, estrogen, glucocorticoid, mineralocorticoid, and progesterone receptors. Antiestrogen or estrogen receptor (ER)targeted therapies to block ER action remain the primary treatment of luminal breast cancers. Although this strategy is successful, ;40% of patients eventually relapse due to endocrine resistance. The majority of hormone-independent tumors retain some level of SR expression, but sidestep hormone ablation treatments. SRs are known to crosstalk extensively with kinase signaling pathways, and this interplay has been shown to bypass ER-targeted therapies in part by providing alternative proliferation and survival signals that enable hormone independence. Modified receptors adopt alternate conformations that resist antagonism or promote agonism. SR-regulated transcription and SR-binding events have been classically studied as single receptor events using single hormones. However, it is becoming increasingly evident that individual steroids and SRs rarely act alone. Emerging evidence shows that coexpressed SRs crosstalk with each other in hormone-driven cancers, such as breast and prostate. Crosstalk between related SRs allows them to modulate signaling and transcriptional responses to noncognate ligands. This flexibility can lead to altered genomic binding and subsequent changes in SR target gene expression. This review will discuss recent mechanistic advances in elucidating SR crosstalk and the implications for treating hormone-driven cancers. Understanding this crosstalk (i.e., both opposing and collaborative) is a critical step toward expanding and modernizing endocrine therapies and will ultimately improve patient outcomes.

AB - Steroid hormone receptors (SRs) have a multitude of functions in human biology and disease progression. The SR family of related ligand-activated transcription factors includes androgen, estrogen, glucocorticoid, mineralocorticoid, and progesterone receptors. Antiestrogen or estrogen receptor (ER)targeted therapies to block ER action remain the primary treatment of luminal breast cancers. Although this strategy is successful, ;40% of patients eventually relapse due to endocrine resistance. The majority of hormone-independent tumors retain some level of SR expression, but sidestep hormone ablation treatments. SRs are known to crosstalk extensively with kinase signaling pathways, and this interplay has been shown to bypass ER-targeted therapies in part by providing alternative proliferation and survival signals that enable hormone independence. Modified receptors adopt alternate conformations that resist antagonism or promote agonism. SR-regulated transcription and SR-binding events have been classically studied as single receptor events using single hormones. However, it is becoming increasingly evident that individual steroids and SRs rarely act alone. Emerging evidence shows that coexpressed SRs crosstalk with each other in hormone-driven cancers, such as breast and prostate. Crosstalk between related SRs allows them to modulate signaling and transcriptional responses to noncognate ligands. This flexibility can lead to altered genomic binding and subsequent changes in SR target gene expression. This review will discuss recent mechanistic advances in elucidating SR crosstalk and the implications for treating hormone-driven cancers. Understanding this crosstalk (i.e., both opposing and collaborative) is a critical step toward expanding and modernizing endocrine therapies and will ultimately improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85056565222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056565222&partnerID=8YFLogxK

U2 - 10.1210/en.2018-00831

DO - 10.1210/en.2018-00831

M3 - Article

C2 - 30307542

AN - SCOPUS:85056565222

VL - 159

SP - 3897

EP - 3907

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 12

ER -